Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adial Pharmaceuticals (ADIL) Share-based Compensation (2022 - 2024)

Adial Pharmaceuticals' Share-based Compensation history spans 3 years, with the latest figure at $180202.0 for Q4 2024.

  • For Q4 2024, Share-based Compensation fell 89.37% year-over-year to $180202.0; the TTM value through Dec 2024 reached $679541.0, down 78.5%, while the annual FY2025 figure was $676200.0, 15.14% down from the prior year.
  • Share-based Compensation for Q4 2024 was $180202.0 at Adial Pharmaceuticals, down from $188261.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.0 million in Q2 2022 and bottomed at $93750.0 in Q1 2022.
  • The 3-year median for Share-based Compensation is $363975.5 (2023), against an average of $601170.2.
  • The largest annual shift saw Share-based Compensation skyrocketed 390.22% in 2023 before it plummeted 89.37% in 2024.
  • A 3-year view of Share-based Compensation shows it stood at $734144.0 in 2022, then soared by 130.81% to $1.7 million in 2023, then tumbled by 89.37% to $180202.0 in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Share-based Compensation are $180202.0 (Q4 2024), $188261.0 (Q3 2024), and $202378.0 (Q2 2024).